ArticleChembiochem : a European journal of chemical biology2025
Biofilm Eradication Using Water-Soluble Silver(I) Coumarin Complexes.
Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biofilm Eradication Using Water-Soluble Silver(I) Coumarin Complexes.Chembiochem : a European journal of chemical biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Water-soluble photostable coumarin acetate complexes of silver(I) are successfully synthesized and characterized and found to have the ability to eradicate preformed MRSA biofilms. Substitution with short PEG chains at the 4-position of the coumarin ring allows the subsequent synthesis of water-soluble coumarin oxyacetate ligands which successfully allowed silver(I) complex formation. The new complexes are characterized by IR and NMR spectroscopy, microanalysis and high-resolution mass spectrometry where possible. Previous unPEGylated analogs has shown excellent antimicrobial activity against the pathogenic bacteria MRSA, Escherichia coli and Pseudomonas aeruginosa and that activity is maintained in the PEGylated complexes. However, the solubility of the un-PEGylated analogs is limited to DMSO, and those silver(I) complexes are unstable in ambient light conditions. Both issues are resolved with the new PEGylated complexes reported here and importantly the ability to eradicate preformed biofilms of MRSA is demonstrated. In addition, a triphenylphosphine adduct complex is also synthesized, but this complex has reduced activity compared to the simple PEGylated complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.